GTS Securities’s Amplify Weight Loss Drug & Treatment ETF THNR Stock Holding History

GTS Securities’s Portfolio THNR Stock Details THNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,761	Closed	-$240K	–	1942
2026 Q1	$240K	Buy	+9,761	New	+$249K	0.01%	1243
2025 Q2	–	Sell	-33,373	Closed	-$719K	–	1669
2025 Q1	$719K	Buy	33,373 +8,506	+34%	+$194K	0.03%	526
2024 Q4	$561K	Buy	24,867 +12,127	+95%	+$300K	0.03%	561
2024 Q3	$341K	Buy	+12,740	New	+$342K	﹤0.01%	3186

Other funds holding THNR

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

GFA

Godfrey Financial Associates Glenmont, New York $131M AUM

GTS Securities's THNR Position: Q2 2026 in Review

GTS Securities sold out of Amplify Weight Loss Drug & Treatment ETF (THNR) in Q2 2026, closing a stake of 9,761 shares — an estimated $240K sold.

GTS Securities first reported a position in THNR in Q3 2024 and held it in 4 quarters. The position peaked at $719K in Q1 2025. 4 funds tracked by Wall St. Rank hold THNR as of Q2 2026.

GTS Securities reported no remaining Amplify Weight Loss Drug & Treatment ETF position as of Q2 2026 after selling out during the quarter.
GTS Securities sold 9,761 Amplify Weight Loss Drug & Treatment ETF shares in Q2 2026, an estimated $240K.
GTS Securities first reported a position in Amplify Weight Loss Drug & Treatment ETF in Q3 2024 and held it in 4 quarters.
GTS Securities's Amplify Weight Loss Drug & Treatment ETF position peaked at $719K in Q1 2025.
4 funds tracked by Wall St. Rank held Amplify Weight Loss Drug & Treatment ETF as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.